Skip to main content
Novartis
language-selector-globe Philippines | en
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe Philippines
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Novartis in Philippines 
      • Strategy 
      • Diversity and Inclusion 
      • People and Culture 
      • Products 
      • Country Leadership Team 
      • Contact 
      Novartis Philippines About
      About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient resources 
      • Products 
      • Adverse Event Reporting 
      Patients and Caregivers
      Patients and Caregivers
    • Healthcare Professionals 
      • Healthcare professional country resource 
      • Products 
      • Novartis Pipeline 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      Healthcare Professionals
      Healthcare Professionals
    • ESG 
      • Financial Transparency for Philippines 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
      • Ethics, Risk and Compliance 
      • Access 
      • Environmental Sustainability 
      • Global Health 
      ESG
      ESG
    • News 
      • News Archive 
      • Stories 
      • Contacts 
      A photo of people in a meeting hall
      News
    • Careers 
      • Career Search 
      • Meet the teams 
      • Personal Growth 
      • Early Talent 
      • How We Work 
      • Well-being 
      • Diversity and Inclusion 
      • Career Programs 
      • Awards and Recognition 
      Woman wearing a red shirt
      Careers
    • Coronavirus 
      Coronavirus under the microscope
      Coronavirus
    Home Novartis Philippines
    Home

What is PIK3CA and why is it important to you?

Back to Previous Page
What is PIK3CA and why is it important to you?
Description

A leaflet informing about the PIK3CA mutation and why does it occur in breast cancer.

Download (PDF 1.99 MB)

Related Items

  • Improving Breast Cancer Survivorship in the Philippines: Policy and Program Implications from The Pink Initiative
    Document
    lock
    Breast Cancer
    Improving Breast Cancer Survivorship in the Philippines: Policy and Program Implications from The Pink Initiative
  • beyond-the-pink-ribbon
    PDF
    lock
    Breast Cancer
    2024 PNCS Novartis Symposium
  • See What Lies Beneath Breast Cancer
    Video
    lock
    Breast Cancer
    See What Lies Beneath Breast Cancer - Video
  • Ano ang PIK3CA gene mutations?
    Document
    lock
    Breast Cancer
    Hindi Pare-pareho ang mga uri ng kanser sa suso

Novartis Philippines

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
NPC Seal of Registration
Footer Bottom
© 2024 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for an audience in the Philippines